An observational study in Hypopharyngeal Cancer, Laryngeal Cancer and Head and Neck Cancer, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hypopharyngeal Neoplasms with a site in China — 16 open to participants now, 17 under way, 2 of them phase 3. Hypopharyngeal Neoplasms · China.
Among the 21 studies in Hypopharyngeal Neoplasms with a site in China, this one is the only one that started in 2026, is one of 2 observational ones, reaches primary completion later than 15 of the 16 other live ones, and was the 21st registered.
148 studies on the registry are indexed under Hypopharyngeal Neoplasms; 45 are open to participants now.
Browse Hypopharyngeal Neoplasms studies →16 of the 21 studies in Hypopharyngeal Neoplasms with a site in China are open now. Recruiting first, the newest first:
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–75
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18–90
Sun Yat-sen University · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18–75
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 38 Hypopharyngeal Neoplasms studies recruiting now, 23 (61%) set no upper age limit and 8 (21%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 163 across 22 observational studies indexed under Hypopharyngeal Neoplasms.
Median enrollment 63 across the 19 interventional studies, 2,000 across the 2 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 21 has an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 250 studies on the registry; 147 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 1 study filed under Hypopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies in Hypopharyngeal Neoplasms with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07137039The First Affiliated Hospital of Xiamen UniversityNeoadjuvant Treatment of Locally Advanced Hypopharyngeal Cancer With Adebrelimab Combined With TP Chemotherapy Regimen | 2027-08-20 |
| NCT06039631Fudan UniversityNeoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer | 2027-09-01 |
| NCT05494190Eye & ENT Hospital of Fudan UniversityThe Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma | 2027-11 |
| NCT07248956Eye & ENT Hospital of Fudan UniversityNeoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Hypopharyngeal Neoplasms with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to develop and validate a clinical prediction model for the risk of head and neck cancerous lesions using deep learning combined with AI algorithms, based on multi-center clinical data.
Vocal health has emerged as a prominent public health challenge. Phonation relies on precise neuromuscular and respiratory coordination, a physiological process frequently compromised by systemic senescence, multimorbidity, and neuromuscular degeneration. This complex pathophysiological interplay makes it exceedingly difficult to clinically distinguish early-stage laryngeal malignancies from common benign voice disorders (e.g., vocal fold cysts, vocal process granulomas, and Reinke's edema). Because both entities typically present with non-specific hoarseness or globus sensation, the difficulty of early screening and accurate differential diagnosis is substantially amplified.
Currently, the diagnosis of voice disorders relies heavily on laryngoscopy. However, owing to the unequal distribution of medical resources, primary and community care settings generally lack effective screening tools for laryngeal malignancies during initial consultations, often leading to delayed referrals for high-risk patients. Furthermore, there is a profound disparity in endoscopic interpretation expertise across different healthcare tiers. The visual features of certain precancerous lesions (such as dysplastic leukoplakia) and early-stage malignancies overlap considerably, resulting in a high risk of missed diagnoses or unnecessary biopsies of benign lesions. Therefore, systematically incorporating multidimensional indicators-including demographics (e.g., age), smoking and alcohol history, and clinical symptomatology-into risk assessment is crucial for the early detection of malignancies and the optimal allocation of healthcare resources.
In recent years, deep learning-based artificial intelligence (AI) has demonstrated tremendous potential in medical image feature extraction, capable of capturing subtle morphological textures imperceptible to the human eye. However, the oncogenesis and progression of laryngeal malignancies are driven by a confluence of multidimensional factors. When confronted with complex, real-world clinical scenarios, unimodal imaging models often suffer from decreased generalizability and elevated false-positive rates due to the absence of the patient's demographic, symptomatic, and behavioral exposure context. Real-world clinical decision-making is not an isolated image-interpretation task; rather, it requires the systematic integration of visual features with multidimensional clinical metadata. Developing an intelligent diagnostic framework capable of fusing multimodal data is therefore essential to overcome the application bottlenecks of current unimodal AI imaging tools.
Addressing these clinical pain points and technical limitations, this study leveraged a national multicenter cohort encompassing approximately 11,000 patients with voice disorders to develop and validate a two-stage, multimodal AI risk stratification and diagnostic framework. In the first stage, by integrating demographic characteristics, behavioral exposures, and clinical symptomatology, the investigators developed a non-invasive, low-cost Clinical Screening Model. This tool is designed to provide primary care settings and patients with an immediate, efficient early-warning system for malignancies. In the second stage, building upon this initial risk stratification, the investigators employed deep learning algorithms to extract microscopic visual features from endoscopic images, culminating in a Multimodal Diagnostic Model. This model achieves precise multiclass classification among laryngeal malignancies, common benign vocal fold lesions, and normal laryngeal anatomy. Furthermore, the investigators deployed a cloud-based web application to facilitate real-time risk estimation.
Ultimately, by providing this clinical-grade AI diagnostic assistant, this study aims to optimize the hierarchical screening and diagnostic pathways for voice disorders, thereby empowering general practitioners and primary care otolaryngologists to enhance the quality of clinical decision-making and diagnostic accuracy.
The study cohort comprised outpatients and inpatients from the otolaryngology departments of the participating medical centers, who underwent laryngoscopy primarily for initial presenting symptoms such as pharyngeal discomfort and hoarseness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age ≥ 18 years old. Patients with complete clinical data information and laryngoscopic images.
Exclusion Criteria:
Refusal to sign the form. Incomplete clinical data. Known diagnosis of other head and neck (thyroid cancer, malignant parotid tumors, etc.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comprised patients with histopathologically confirmed head and neck malignant lesions, primarily including laryngeal and hypopharyngeal carcinomas.
Consisted of patients absent of malignant findings, encompassing individuals with normal laryngeal anatomy and those diagnosed with benign vocal fold lesions (e.g., polyps, cysts, and nodules).
Laryngoscopic report diagnosis
those data will be collected via medical history records,"The laryngoscopic report diagnosis" primarily consists of detailed diagnostic classifications for various vocal fold and laryngeal pathologies.
Time frame: During the first outpatient visit (Day 1)
Demographic data
Demographic data primarily includes demographic characteristics, behavioral habits, medical history, and lifestyle factors.
Time frame: During the first outpatient visit (Day 1)
VHI-10
those data will be collected via questionnaire ,Voice-related quality of life was assessed using the Voice Handicap Index (VHI). Total scores range from 0 to 120. Higher scores indicate greater voice-related daily life handicap (worse outcome).
Time frame: During the first outpatient visit(Day 1)
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Raw data will not be directly shared and will only be provided when necessary. All research codes involved in this study will be made publicly available.
Started Apr 2026 (actual). Primary completion is estimated for Nov 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →